T-cell Therapy

A targeted strategy for cancer treatment and HPV treatment

T cell therapy has been investigated and developed for the treatment of solid tumors. While these therapies have shown significant success in treating certain hematological malignancies, their application to solid tumors poses additional challenges.

Solid tumors have a more complex microenvironment compared to hematological cancers, which can make it harder for T cells to effectively infiltrate and eliminate cancer cells. Additionally, solid tumors often express fewer specific tumor-associated antigens that can be targeted by T cells.

Despite these challenges, researchers are exploring various strategies to improve the efficacy of T cell therapy for solid tumors:

  1. Enhancing T cell trafficking: Efforts are being made to modify T cells to improve their ability to migrate into solid tumors and penetrate the tumor microenvironment.

  2. Combination therapies: T cell therapy is being investigated in combination with other treatments, such as immune checkpoint inhibitors or chemotherapy, to create a more favorable environment for T cell activity and enhance overall treatment outcomes.

  3. Targeting multiple antigens: Instead of targeting a single antigen, researchers are exploring ways to engineer T cells with receptors that can recognize multiple tumor-associated antigens, increasing the chances of effective tumor cell killing.

  4. Overcoming immunosuppression: Solid tumors often employ immunosuppressive mechanisms to evade immune surveillance. Strategies to counteract these mechanisms, such as using immune checkpoint inhibitors, can help enhance the effectiveness of T cell therapy.

While progress is being made, it’s important to note that T cell therapy for solid tumors is still an area of active research and clinical trials. The efficacy and safety of these approaches are being studied, and more data is needed to fully understand their potential benefits in treating solid tumors.

T cell therapy is a targeted treatment, it is effective for cancer treatment and HPV treatment. The T cells are collected and trained ex-vivo to acquire abilities to recognizing and attacking cancer cells and HPV.

Patients with lung cancer, breast cancer, colon cancer, prostate cancer, cervical cancer, ovarian cancer, kidney cancer and HPV etc can be accepted for the treatment after being assessed.

Possible Improvements

ACTL cancer immunotherapy targets the tumor cells and stops them from further spreading or destroy them. It is more effective to receive ACTL treatment after the surgery, radiotherapy and chemotherapy. It also reverses the drug-resistance, patients may respond again to radiation and chemotherapy after the ACTL therapy. It is important to note that improvement rate greatly depends on the nature and level of the disease at the time of treatment. And as with any cancer treatment methods, improvement may vary from one patient to another and cannot be guaranteed.

* As with any cell based treatment, improvements may vary from a patient to another and cannot be guaranteed.

ACTL refers to AAV-DC-CTL (adeno-associated virus, dendritic cells, cytotoxic T lymphocytes). The treatment is dendritic cells (DC) and cytotoxic T lymphocytes (CTL) based.

ACTL tumor targeted immunotherapy technology uses non-pathogenic adeno-associated virus (AAV) to infect the monocytes (Mo) in the peripheral blood. After being induced with cytokines, the monocytes will transform to the powerful antigen presenting dendritic cells (DCs).

The tumor antigen-specificity possessed during the process is called targeting ability. Therefore, the CTLs activated by the rAAV-infected DCs are able to eliminate the tumor cells which present positive for one or several types of tumor related antigens, the cells present negative for such antigens will be not affected.

Advantages of ACTL Treatment

Improved Targeting Ability

After genetic modification, the rAAV can carry tumor specific antigens to infect the DC and activate the attacking ability of the CTLs. These CTLs are tumor antigen targeted, cause no harm to the normal cells.

A patient is qualified to receive the ACTL immunotherapy as long as the treatment requirement is met. Unlike the immunotherapies in early ages, the cell cultivation process of the ACTL immunotherapy has been upgraded to fulfill the needs in clinical treatment. The process was simplified and infection efficiency was improved that with only one transfection, over 90% of the dendritic cells (DCs) will be infected with the antigens carried by the AAV. The attacking ability of the CTLs will be induced and significantly enhanced by these DCs.

Reversibility of Drug Resistance

The ACTL immunotherapy can not only reverse the drug-resistance developed during the hormone treatment, but possibly reverse the tumor cells’ resistance to the molecular targeted drugs, such as Iressa and Avastin.

Immunity Enhancement

ACTL immunotherapy can increase the IL-12 and IFN-y’s expression levels of the DCs, in contrary, the expression levels of IL-10 can be decreased, the mixture of rAAV-infected DC and lymphocytes will increase the number of the DC8+T cells, the number of the CD4+T cells will be decreased. Therefore the CTL’s attacking ability will be enhanced, and the immunity will be improved to fight against cancer.

Treatment Process

  • Blood collection from patient’s vein
  • Centrifuge and get the peripheral blood monocytes (PBMC)
  • Lymphocytes and monocytes are separated. The monocytes will be infected by the rAAV, and cytokines will be added to induce the production of the dendritic cells (DCs)
  • Culture mature DC and lymphocytes together to induce the T cells
  • Infuse activated T cells to patient’s body to complete the treatment. The entire process takes about 12 to 18 days.

Why China being the prior destination for immunotherapy?

0 %+
Effectiveness
0 %
Cheaper
0 +
Clinical Trials
0 +
Hospitals

China has seen rapid growth in its biotech industry, particularly in the area of CAR T-cell therapy. Many Chinese biotech firms have developed their own CAR T-cell therapies and are actively seeking partnerships with international pharmaceutical companies. As the second-largest country in terms of the number of CAR T-cell therapy clinical trials, China’s research efforts reflect its commitment to advancing this innovative treatment approach.

Moreover, China has implemented various measures to make CAR T-cell therapy more accessible and affordable for patients. These patient-friendly pricing strategies have indeed contributed to making China an attractive destination for international patients for innovative therapies like CAR T-cell therapy. Comparatively, the cost of CAR T-cell therapy in China may be relatively more affordable than in other countries.

Effective and affordable immunotherapy and CAR T-cell Therapy?

Contact us and get detailed information about getting advanced immunotherapy and CAR T-cell therapy for the treatment of solid tumors, blood cancers and HPV infection.

What Do We Offer?

At Immunotherapy China, we offer a range of cell-based immunotherapy for cancer treatment and HPV treatment.

CAR T-cell Therapy

The latest technologies effective in the treatment of lymphoma, leukemia and myeloma.
Hot

Tumor-specific T Cell Therapy

Advanced technology to train patient's immune system to recognize and attack cancer cells.
HOT

Natural Killer Cell Therapy

NK cell therapy utilizes the body's immune cells to destroy cancer cells and boost immune system.

Dendritic Cell Therapy

DC therapy stimulates the immune system and enhance its ability to recognize and attack cancer cells.

TCR T-cell Therapy

Modifying a patient's T cells to express specific T-cell receptors, enabling them to target and destroy cancer cells.

TIL Therapy

Isolated and expended from a patient's tumor, reinfuse them to enhance their activity for targeting cancer cells.

FAQs

How Immune System fight cancer?

Why Consider Immunotherapy?

Effectiveness of Immunotherapy